Could light therapy help save sight in dry macular degeneration?

NCT ID NCT02725762

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether a non-invasive light treatment called photobiomodulation can improve vision and slow vision loss in people with dry age-related macular degeneration (AMD). Participants receive either active light therapy or a sham (inactive) treatment over 12 months. The goal is to see if this approach can safely help preserve eyesight in those with the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
light therapy (photobiomodulation) via the LT-300 device
What this could lead to
If effective, this could offer a non-invasive treatment option to help preserve vision in people with dry age-related macular degeneration.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to everyone. The treatment may not improve vision or could have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • 1929 Bayview Avenue, Unit 117

    Toronto, Ontario, M4G 3E8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.